Filing Details

Accession Number:
0001237899-17-000019
Form Type:
4
Zero Holdings:
No
Publication Time:
2017-08-09 16:03:52
Reporting Period:
2017-08-07
Filing Date:
2017-08-09
Accepted Time:
2017-08-09 16:03:52
SEC Url:
Form 4 Filing
Issuer
Cik Name Symbol Sector (SIC) IRS No
872589 Regeneron Pharmaceuticals Inc REGN Pharmaceutical Preparations (2834) 133444607
Insiders
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1585160 E Robert Landry 777 Old Saw Mill River Road
Tarrytown NY 10591
Svp Finance & Cfo No Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2017-08-07 2,000 $272.70 9,099 No 4 M Direct
Common Stock Disposition 2017-08-07 1,167 $466.98 7,932 No 4 F Direct
Common Stock Disposition 2017-08-07 307 $466.98 7,625 No 4 F Direct
Common Stock Disposition 2017-08-08 100 $469.91 7,525 No 4 S Direct
Common Stock Disposition 2017-08-08 100 $471.00 7,425 No 4 S Direct
Common Stock Disposition 2017-08-08 100 $472.54 7,325 No 4 S Direct
Common Stock Disposition 2017-08-08 226 $473.57 7,099 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 F Direct
No 4 F Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Non-Qualified Stock Option (right to buy) Disposition 2017-08-07 2,000 $0.00 2,000 $272.70
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
64,000 2023-09-09 No 4 M Direct
Reported Non-Derivative Holdings
Sec. Name Remaning Holdings Nature of Ownership Explanation
Common Stock 83 Indirect By 401(k) Plan
Footnotes
  1. Disposition/acquisition made pursuant to a plan intended to comply with Rule 10b5-1(c).
  2. Represents volume-weighted average price of sales of 226 shares of Company stock on August 8, 2017 at prices ranging from $473.27 to $472.94. Upon request by the Commission staff, the Company, or a security holder of the Company, the reporting person will provide full information regarding the number of shares sold by the reporting person on August 8, 2017 at each separate price.
  3. The stock option award vests in four equal annual installments, commencing one year after the date of grant.